NewAmsterdam Pharma (NAMS) Total Current Liabilities (2021 - 2026)

NewAmsterdam Pharma has reported Total Current Liabilities for 6 years, with the latest figure at $67.4 million in Q1 2026.

• Quarterly Total Current Liabilities rose 64.79% year-over-year to $67.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.4 million (up 64.79% YoY) and the FY2025 annual result came in at $85.8 million, down 19.76% from the prior year.
• Total Current Liabilities declined to $67.4 million in Q1 2026 per NAMS's latest filing, from $85.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $106.9 million in Q4 2024 and troughed at $41743.9 in Q2 2023.
• A 5-year average of $52.4 million and a median of $47.6 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 108435.58% in 2024, then slumped 31.5% in 2025.
• Over 5 years, Total Current Liabilities stood at $36.2 million in 2022, then jumped by 37.92% to $49.9 million in 2023, then jumped by 114.28% to $106.9 million in 2024, then dropped by 19.76% to $85.8 million in 2025, then fell by 21.41% to $67.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $67.4 million, $85.8 million, and $58.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.